The FDA has approved natalizumab (Tysabri) for the treatment of moderate-to-severe Crohn’s disease in patients with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional Crohn’s disease therapies.

References and Resources
FDA Approves Tysabri to Treat Moderate-to-Severe Crohn’s Disease

Sponsored by The Doctor’s Channel